Jim Sang

Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

Weiwen Ying, Zhenjian Du, Lijun Sun et al. · Molecular Cancer Therapeutics · 2011 · 231 citations

Medicine, Oncology, Pharmacology +11

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90

Jens Sydor, Emmanuel Normant, Christine Pien et al. · Proceedings of the National Academy of Sciences · 2006 · 227 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Jim Sang, Jaime Acquaviva, Julie C. Friedland et al. · Cancer Discovery · 2013 · 210 citations

Medicine, Oncology, Pharmacology +17

Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer

Takeshi Shimamura, Samanthi A. Perera, Kevin P. Foley et al. · Clinical Cancer Research · 2012 · 166 citations

Medicine, Oncology, Pharmacology +13

Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib

Jaime Acquaviva, Donald L. Smith, John-Paul Jimenez et al. · Molecular Cancer Therapeutics · 2014 · 102 citations

Medicine, Oncology, Pharmacology +14